M S Murgueitio1, S Ebner2, P Hörtnagl3, C Rakers1, R Bruckner4, P Henneke5, G Wolber1, S Santos-Sierra6. 1. Pharmaceutical Chemistry, Institute of Pharmacy, Freie Universität Berlin, Königin-Luise Str. 2-4, 14195 Berlin, Germany. 2. Department of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Medical University Innsbruck, Innrain 66, 6020 Innsbruck, Austria. 3. Central Institute of Blood Transfusion and Immunology, Medical University Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria. 4. Section of Biochemical Pharmacology, Medical University Innsbruck, Peter Mayr Str.1, 6020 Innsbruck, Austria. 5. Center for Chronic Immunodeficiency (CCI) and Center for Pediatrics and Adolescent Medicine, Medical Center, University of Freiburg, Faculty of Medicine, Breisacher Straße 115, 79106 Freiburg, Germany. 6. Section of Biochemical Pharmacology, Medical University Innsbruck, Peter Mayr Str.1, 6020 Innsbruck, Austria. Electronic address: Sandra.santos@i-med.ac.at.
Abstract
BACKGROUND: Emergent therapies in anticancer vaccination use Toll-like receptors (TLRs) agonists as dendritic cell (DC) vaccine adjuvants. DCs from the patient are isolated, stimulated with TLR agonists and tumor antigens ex vivo and then infused back into the patient. Although some TLR ligands have been tested in clinical trials, novel TLR agonists with improved immunomodulatory properties are essential to optimize treatment success. We report on the discovery of small-molecule TLR2 agonists, with favorable properties as synthetic adjuvants. METHODS: We performed a shape- and featured-based similarity virtual screening against a commercially available compound library. The selected virtual hits were experimentally tested in TLR2-reporter cells and their activity in phagocytes and DCs was characterized. A binding model of the compounds to TLR2 (docking studies) was proposed. RESULTS: Through a virtual screening approach against a library of three million compounds four virtual hits (AG1, AG2, AG3, AG4) were found to synergistically augment the NF-kB activation induced by the lipopeptide ligand Pam3CSK4 in luciferase reporter assays using HEK293-TLR2 cells. Biacore experiments indicated that AG1-AG4 are ago-allosteric modulators of TLR2 and AG2 bound TLR2 with high affinity (KD 0.8μM). The compounds induced TNF-α production in human peripheral blood mononuclear cells (PBMCs) and they activated DCs as indicated by IL-12 production and upregulation of CD83/CD86. CONCLUSIONS: Following a combined in silico/in vitro approach we have discovered TLR2-agonists (AG1-AG4) that activate human and mouse immune cells. GENERAL SIGNIFICANCE: We introduce four novel TLR2 ago-allosteric modulators that stimulate myeloid cell activity and constitute promising candidates as synthetic adjuvants.
BACKGROUND: Emergent therapies in anticancer vaccination use Toll-like receptors (TLRs) agonists as dendritic cell (DC) vaccine adjuvants. DCs from the patient are isolated, stimulated with TLR agonists and tumor antigens ex vivo and then infused back into the patient. Although some TLR ligands have been tested in clinical trials, novel TLR agonists with improved immunomodulatory properties are essential to optimize treatment success. We report on the discovery of small-molecule TLR2 agonists, with favorable properties as synthetic adjuvants. METHODS: We performed a shape- and featured-based similarity virtual screening against a commercially available compound library. The selected virtual hits were experimentally tested in TLR2-reporter cells and their activity in phagocytes and DCs was characterized. A binding model of the compounds to TLR2 (docking studies) was proposed. RESULTS: Through a virtual screening approach against a library of three million compounds four virtual hits (AG1, AG2, AG3, AG4) were found to synergistically augment the NF-kB activation induced by the lipopeptide ligand Pam3CSK4 in luciferase reporter assays using HEK293-TLR2 cells. Biacore experiments indicated that AG1-AG4 are ago-allosteric modulators of TLR2 and AG2 bound TLR2 with high affinity (KD 0.8μM). The compounds induced TNF-α production in human peripheral blood mononuclear cells (PBMCs) and they activated DCs as indicated by IL-12 production and upregulation of CD83/CD86. CONCLUSIONS: Following a combined in silico/in vitro approach we have discovered TLR2-agonists (AG1-AG4) that activate human and mouse immune cells. GENERAL SIGNIFICANCE: We introduce four novel TLR2 ago-allosteric modulators that stimulate myeloid cell activity and constitute promising candidates as synthetic adjuvants.
Authors: Ying Wang; Lijing Su; Matthew D Morin; Brian T Jones; Yuto Mifune; Hexin Shi; Kuan-Wen Wang; Xiaoming Zhan; Aijie Liu; Jianhui Wang; Xiaohong Li; Miao Tang; Sara Ludwig; Sara Hildebrand; Kejin Zhou; Daniel J Siegwart; Eva Marie Y Moresco; Hong Zhang; Dale L Boger; Bruce Beutler Journal: Proc Natl Acad Sci U S A Date: 2018-08-27 Impact factor: 11.205
Authors: Lijing Su; Ying Wang; Junmei Wang; Yuto Mifune; Matthew D Morin; Brian T Jones; Eva Marie Y Moresco; Dale L Boger; Bruce Beutler; Hong Zhang Journal: J Med Chem Date: 2019-03-13 Impact factor: 7.446
Authors: Matthew D Morin; Ying Wang; Brian T Jones; Yuto Mifune; Lijing Su; Hexin Shi; Eva Marie Y Moresco; Hong Zhang; Bruce Beutler; Dale L Boger Journal: J Am Chem Soc Date: 2018-10-16 Impact factor: 15.419
Authors: Marcel Bermudez; Maria Grabowski; Manuela S Murgueitio; Markus Tiemann; Péter Varga; Thomas Rudolf; Gerhard Wolber; Günther Weindl; Jörg Rademann Journal: ChemMedChem Date: 2020-06-03 Impact factor: 3.466